Magnetic pulses to the brain may quiet multiple neurologic symptoms

NCT ID NCT06429748

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study investigates whether repetitive transcranial magnetic stimulation (rTMS) can reduce a range of neurologic symptoms, such as sleep difficulties, in adults aged 22 to 70. Participants receive rTMS sessions, and researchers track changes in symptom scores using patient questionnaires. The goal is to see if this non-invasive brain stimulation offers symptom relief and how long any benefits last.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
repetitive transcranial magnetic stimulation (rTMS)
What this could lead to
If it works, this could point toward a non-drug option for managing multiple neurologic symptoms, such as sleep problems.
What could go wrong
This is a small, early-stage study with only 20 participants, so results may not apply widely. The treatment may not provide lasting symptom relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

May 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults, 22 to 70 years of age 2. Voluntarily provides written informed consent and agree to comply with study procedures, including attending all study visits and completing all study assessments. 3. Score \> or = 8 on ISI scale 4. If subject is on any psychiatric or sleep medication, dose must be stable for two weeks prior to enrollment and remain stable throughout the trial. 5. If female, not breastfeeding, no known or suspected pregnancy, a status of nonchildbearing potential or use of an acceptable form of birth control. 6. Subject on stable dose regime for other concurrent medications like hormonal therapy for menopause transition etc. Exclusion Criteria: 1. Subject meets any one or more of the contraindications for TMS Therapy per current treatment guidelines as determined by the PI. 2. History of head trauma associated with loss of consciousness or diagnosed as concussion. 3. History of fainting, syncope, hearing problems or ringing in the ears (tinnitus) 4. Has any metallic implant(s) in or near the head (e.g., pacemaker, defibrillator, neurostimulator, etc.) including any splinters, fragments, clips, etc. 5. Has an implanted stimulator device (including device leads) in or near the head. (e.g. deep brain stimulator, cochlear implant, vagus nerve stimulator.) 6. Has medication infusion device. 7. Subjects with any prior TMS or MRI complications, or any other issues/circumstance which, in the opinion of the investigator, might interfere with safety, study participation, or which might confound data interpretation. 8. PHQ-9 total score \> or = 10 or QIDS total score \> or = 11. 9. Drug abuse or dependence of the illicit substance. (Abuse or Dependence, as defined by DSM-V-TR) 10. Current diagnosis or known history of neurologic disease (e.g., epilepsy, convulsion, seizure) 11. Other known disorder (e.g., narcolepsy, a breathing-related sleep disorder like Obstructive Sleep Apnea, a circadian rhythm sleep-wake disorder, a parasomnia) as defined by DSM-V-TR. 12. Has a clinically significant abnormality on the screening examination. 13. Participation in any clinical trial with an investigational drug or device within the past month or concurrent with study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neurologic symptoms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Neurologic Manifestations

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Charlotte Skin and Laser

    Charlotte, North Carolina, 28207, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.